



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-183/S-022

Bristol-Myers Squibb Company
Attention: Beatrice Anduze-Faris, M.D.
Group Director, Global Mature Brands
Global Regulatory Sciences
Rte 206 & Provinceline Rd
Princeton NJ, 08540

Dear Dr. Anduze-Faris:

Please refer to your supplemental new drug application dated and received November 19, 2008, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for VIDEX EC (didanosine) Delayed Release Capsules.

We acknowledge receipt of your submission(s) dated December 12, 2008, May 22, 2009 and June 4, 2009.

This supplemental new drug application provides for revisions to the U.S. Package Insert to include results from a drug-drug interaction study evaluating the bioavailability of didanosine from the delayed release capsules formulation (VIDEX EC) relative to the chewable, dispersible buffered tablet formulation when co-administered in subjects who were on a stable dose of methadone.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

As soon as possible, but no later than 14 days from the date of this letter, please submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format as described at <http://www.fda.gov/oc/datacouncil/spl.html> that is identical to the enclosed labeling (text for the package insert and text for the patient package insert). Upon receipt, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission, "SPL for approved NDA 21-183/S-022."

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert and text for the patient package insert).

Submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package insert directly to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road

Beltsville, MD 20705-1266

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH
Food and Drug Administration
Suite 12B05
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Stacy Powers Newalu, M.P.H., Regulatory Project Manager, at (301) 796-3978.

Sincerely,

{See appended electronic signature page}

Debra Birnkrant, M.D.
Director
Division of Antiviral Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

Enclosure (clean copy of approved labeling)

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Kendall Marcus

6/10/2009 05:18:25 PM